日本高潮视频在线观看-亚洲中文字幕永不卡-精品亚洲一区二区三区-伦理片夜夜躁狠狠躁日日躁-日本最新免费不卡二区-国产精品口爆一区二区三区-av一区二区三区高清-大鸡巴疯狂抽插小穴视频-日韩中文国产在线观看免费视频

Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Pyrococcus abyssi UPF0128 protein PYRAB08320 (PYRAB08320) CSB-YP895525FHV
CSB-EP895525FHV
CSB-BP895525FHV
CSB-MP895525FHV
CSB-EP895525FHV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus abyssi Pyridoxal biosynthesis lyase pdxS (pdxS) CSB-YP895526FHV
CSB-EP895526FHV
CSB-BP895526FHV
CSB-MP895526FHV
CSB-EP895526FHV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus abyssi Probable deoxyhypusine synthase (dys) CSB-YP895527FHV
CSB-EP895527FHV
CSB-BP895527FHV
CSB-MP895527FHV
CSB-EP895527FHV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus abyssi Glycerol-1-phosphate dehydrogenase [NAD (P)+] (egsA) CSB-YP895528FHV
CSB-EP895528FHV
CSB-BP895528FHV
CSB-MP895528FHV
CSB-EP895528FHV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus abyssi Uncharacterized protein PYRAB06580 (PYRAB06580), partial CSB-YP895529FHV
CSB-EP895529FHV
CSB-BP895529FHV
CSB-MP895529FHV
CSB-EP895529FHV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus abyssi Uncharacterized HTH-type transcriptional regulator PYRAB06490 (PYRAB06490) CSB-YP895530FHV
CSB-EP895530FHV
CSB-BP895530FHV
CSB-MP895530FHV
CSB-EP895530FHV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus abyssi Peptidyl-tRNA hydrolase (pth) CSB-YP895531FHV
CSB-EP895531FHV
CSB-BP895531FHV
CSB-MP895531FHV
CSB-EP895531FHV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus abyssi Probable exosome complex exonuclease 2 (PYRAB06110) CSB-YP895532FHV
CSB-EP895532FHV
CSB-BP895532FHV
CSB-MP895532FHV
CSB-EP895532FHV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus abyssi Type II DNA topoisomerase VI subunit A (top6A) CSB-YP895533FHV
CSB-EP895533FHV
CSB-BP895533FHV
CSB-MP895533FHV
CSB-EP895533FHV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus abyssi HTH-type transcriptional regulator lrpA (lrpA) CSB-YP895534FHV
CSB-EP895534FHV
CSB-BP895534FHV
CSB-MP895534FHV
CSB-EP895534FHV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus abyssi Pyruvoyl-dependent arginine decarboxylase (pdaD) CSB-YP895535FHV
CSB-EP895535FHV
CSB-BP895535FHV
CSB-MP895535FHV
CSB-EP895535FHV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus abyssi 50S ribosomal protein L18e (rpl18e) CSB-YP895536FHV
CSB-EP895536FHV
CSB-BP895536FHV
CSB-MP895536FHV
CSB-EP895536FHV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus abyssi UPF0235 protein PYRAB05010 (PYRAB05010) CSB-YP895537FHV
CSB-EP895537FHV
CSB-BP895537FHV
CSB-MP895537FHV
CSB-EP895537FHV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus abyssi UPF0292 protein PYRAB04740 (PYRAB04740) CSB-YP895538FHV
CSB-EP895538FHV
CSB-BP895538FHV
CSB-MP895538FHV
CSB-EP895538FHV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus abyssi Chorismate synthase (aroC) CSB-YP895539FHV
CSB-EP895539FHV
CSB-BP895539FHV
CSB-MP895539FHV
CSB-EP895539FHV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus abyssi Acetyl-lysine deacetylase (lysK) CSB-YP895540FHV
CSB-EP895540FHV
CSB-BP895540FHV
CSB-MP895540FHV
CSB-EP895540FHV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus abyssi UPF0278 protein PYRAB03930 (PYRAB03930) CSB-YP895541FHV
CSB-EP895541FHV
CSB-BP895541FHV
CSB-MP895541FHV
CSB-EP895541FHV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus abyssi Probable ribosomal RNA small subunit methyltransferase A (rsmA) CSB-YP895542FHV
CSB-EP895542FHV
CSB-BP895542FHV
CSB-MP895542FHV
CSB-EP895542FHV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus abyssi Putative ABC transporter ATP-binding protein PYRAB03730 (PYRAB03730) CSB-YP895543FHV
CSB-EP895543FHV
CSB-BP895543FHV
CSB-MP895543FHV
CSB-EP895543FHV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus abyssi 50S ribosomal protein L4P (rpl4p) CSB-YP895544FHV
CSB-EP895544FHV
CSB-BP895544FHV
CSB-MP895544FHV
CSB-EP895544FHV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長度(全長或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://m.bdspa.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>



×